Is genetic screening necessary for determining the possibility of venous thromboembolism in cancer patients?
Medical Principles and Practice, vol.21, no.2, pp.160-163, 2012 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 21 Issue: 2
- Publication Date: 2012
- Doi Number: 10.1159/000333394
- Journal Name: Medical Principles and Practice
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.160-163
- Keywords: Cancer, Mutation, Polymorphism, Venous thromboembolism
- Isparta University of Applied Sciences Affiliated: No
Abstract
To determine the risk of an association with some genetic polymorphisms involved in venous thromboembolism (VTE) gene variations (FVL, FV H1299R, FII G20210A, MTHFR C677T, MTHFR A1298C, PAI-1 4G/5G,β-fibrinogen -455 G ] A, FXIII Val34Leu and GpIIIa HPA-1a) in cancer patients. Subjects and Methods: Among 78 cancer patients, 28 who had proven first episode of VTE were selected as the patient group, with 50 control samples selected from age-, sex- and body mass index-matched healthy volunteers (healthy group). The differences in frequency of genetic polymorphisms were found to be statistically insignificant between these two groups. Results: Logistic regression analysis after adjustment for age, sex, smoking and hypertension showed no difference. The screened mutations of these genes were not significantly associated with VTE risk. Conclusion: There is no possible benefit from genetic screening tests regarding VTE in cancer patients. © 2011 S. Karger AG, Basel.